Investing.com - Can Fite Biopharma ADR reported on Friday third quarter earnings that matched analysts' forecasts and revenue that fell short of expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.07 on revenue of $140K. Analysts polled by Investing.com anticipated EPS of $-0.07 on revenue of $232K.
Can Fite Biopharma ADR shares are down 33.71% from the beginning of the year and are trading at $1.180 , down-from-52-week-high.They are under-performing the EUR/USD which is down 0% from the start of the year.
Can Fite Biopharma ADR shares lost 3.27% in intra-day trade the report.
Can Fite Biopharma ADR follows other major Healthcare sector earnings this month
Can Fite Biopharma ADR's report follows an earnings beat by Pfizer on November 2, who reported EPS of $1.34 on revenue of $24.09B, compared to forecasts EPS of $1.08 on revenue of $22.58B.
Novo Nordisk ADR had beat expectations on November 3 with third quarter EPS of $0.8209 on revenue of $5.55B, compared to forecast for EPS of $0.7768 on revenue of $5.39B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar